Literature DB >> 33759025

Clinical use of shear-wave elastography for detecting liver fibrosis in children and adolescents with cystic fibrosis.

Steven Levitte1, Lori W Lee1, Jared Isaacson2, Evan J Zucker2, Carlos Milla3, Richard A Barth2, Zachary M Sellers4.   

Abstract

BACKGROUND: Complications from liver cirrhosis are a leading cause of death in children with cystic fibrosis. Identifying children at risk for developing liver cirrhosis and halting its progression are critical to reducing liver-associated mortality.
OBJECTIVE: Quantitative US imaging, such as shear-wave elastography (SWE), might improve the detection of liver fibrosis in children with cystic fibrosis (CF) over gray-scale US alone. We incorporated SWE in our pediatric CF liver disease screening program and evaluated its performance using magnetic resonance (MR) elastography.
MATERIALS AND METHODS: Ninety-four children and adolescents with CF underwent 178 SWE exams, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT) and platelet measurements. Of these, 27 children underwent 34 MR elastography exams. We evaluated SWE performance using 6-MHz and 9-MHZ point SWE, and 9-MHz two-dimensional (2-D) SWE.
RESULTS: The 6-MHz point SWE was the only method that correlated with MR elastography (r=0.52; 95% confidence interval [CI] 0.20-0.74; P=0.003). SWE of 1.45 m/s distinguished normal from abnormal MR elastography (79% sensitivity, 100% specificity, 100% positive predictive value [PPV], 55% negative predictive value [NPV], area under the receiver operating characteristic [AUROC] curve 0.94). SWE of 1.84 m/s separated mild-moderate (3.00-4.77 kPa) from severe (>4.77 kPa) MR elastography (88% sensitivity, 86% specificity, 78% PPV, 93% NPV, AUROC 0.79). Elevations of AST, ALT, GGT and thrombocytopenia were associated with higher SWE. AST-to-platelet ratio index of 0.42, fibrosis-4 of 0.29, and GGT-to-platelet ratio of 1.43 all had >95% NPV for SWE >1.84 m/s.
CONCLUSION: Given its correlation with MR elastography, SWE might be a clinically useful predictor of liver fibrosis. We identified imaging criteria delineating the use of SWE to identify increased liver stiffness in children with CF. With multicenter validation, these data might be used to improve the detection and monitoring of liver fibrosis in children with CF.

Entities:  

Keywords:  Adolescents; Children; Cystic fibrosis; Cystic fibrosis liver disease; Liver; Magnetic resonance elastography; Shear-wave elastography; Stiffness; Ultrasound

Mesh:

Year:  2021        PMID: 33759025      PMCID: PMC8823212          DOI: 10.1007/s00247-021-05015-w

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  30 in total

1.  Magnetic resonance elastography demonstrates elevated liver stiffness in cystic fibrosis patients.

Authors:  Don Hayes; Ramkumar Krishnamurthy; Houchun Harry Hu
Journal:  J Cyst Fibros       Date:  2018-09-20       Impact factor: 5.482

2.  Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement.

Authors:  Richard G Barr; Giovanna Ferraioli; Mark L Palmeri; Zachary D Goodman; Guadalupe Garcia-Tsao; Jonathan Rubin; Brian Garra; Robert P Myers; Stephanie R Wilson; Deborah Rubens; Deborah Levine
Journal:  Radiology       Date:  2015-06-16       Impact factor: 11.105

3.  Liver Ultrasound Patterns in Children With Cystic Fibrosis Correlate With Noninvasive Tests of Liver Disease.

Authors:  Simon C Ling; Wen Ye; Daniel H Leung; Oscar M Navarro; Alexander Weymann; Wikrom Karnsakul; A Jay Freeman; John C Magee; Michael R Narkewicz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-09       Impact factor: 2.839

4.  Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis.

Authors:  Jaclyn R Stonebraker; Chee Y Ooi; Rhonda G Pace; Harriet Corvol; Michael R Knowles; Peter R Durie; Simon C Ling
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

5.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

6.  Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

Authors:  Roger Chou; Ngoc Wasson
Journal:  Ann Intern Med       Date:  2013-06-04       Impact factor: 25.391

7.  Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease.

Authors:  Peter R Mueller-Abt; Kieran J Frawley; Ristan M Greer; Peter J Lewindon
Journal:  J Cyst Fibros       Date:  2007-09-27       Impact factor: 5.482

Review 8.  Cystic Fibrosis-related cirrhosis.

Authors:  Daniel H Leung; Michael R Narkewicz
Journal:  J Cyst Fibros       Date:  2017-11       Impact factor: 5.482

9.  Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients.

Authors:  Pierre-Yves Boëlle; Dominique Debray; Loic Guillot; Annick Clement; Harriet Corvol
Journal:  Hepatology       Date:  2018-12-28       Impact factor: 17.425

10.  Hepatic and Splenic Acoustic Radiation Force Impulse Shear Wave Velocity Elastography in Children with Liver Disease Associated with Cystic Fibrosis.

Authors:  Teresa Cañas; Araceli Maciá; Rosa Ana Muñoz-Codoceo; Teresa Fontanilla; Patricia González-Rios; María Miralles; Gloria Gómez-Mardones
Journal:  Biomed Res Int       Date:  2015-11-02       Impact factor: 3.411

View more
  2 in total

Review 1.  Ultrasound elastography in children - nice to have for scientific studies or arrived in clinical routine?

Authors:  Hans-Joachim Mentzel; Katja Glutig; Stephanie Gräger; Paul-Christian Krüger; Matthias Waginger
Journal:  Mol Cell Pediatr       Date:  2022-06-06

2.  Non-invasive tools for detection of liver disease in children and adolescents with cystic fibrosis.

Authors:  Antonella Tosco; Angela Sepe; Alice Castaldo; Andrea Catzola; Chiara Cimbalo; Valentina Angelini; Gianfranco Vallone; Roberto Buzzetti; Valeria Raia; Maria Grazia Caprio
Journal:  Transl Pediatr       Date:  2021-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.